Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Share-based Compensation: 2019-2024

Historic Share-based Compensation for Lyell Immunopharma (LYEL) over the last 6 years, with Dec 2024 value amounting to $33.1 million.

  • Lyell Immunopharma's Share-based Compensation fell 31.36% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.3 million, marking a year-over-year decrease of 27.39%. This contributed to the annual value of $33.1 million for FY2024, which is 29.61% down from last year.
  • Per Lyell Immunopharma's latest filing, its Share-based Compensation stood at $33.1 million for FY2024, which was down 29.61% from $47.1 million recorded in FY2023.
  • Over the past 5 years, Lyell Immunopharma's Share-based Compensation peaked at $81.9 million during FY2022, and registered a low of $33.1 million during FY2024.
  • In the last 3 years, Lyell Immunopharma's Share-based Compensation had a median value of $47.1 million in 2023 and averaged $54.1 million.
  • As far as peak fluctuations go, Lyell Immunopharma's Share-based Compensation soared by 111.42% in 2020, and later slumped by 42.53% in 2023.
  • Over the past 5 years, Lyell Immunopharma's Share-based Compensation (Yearly) stood at $33.3 million in 2020, then surged by 87.01% to $62.2 million in 2021, then soared by 31.71% to $81.9 million in 2022, then slumped by 42.53% to $47.1 million in 2023, then declined by 29.61% to $33.1 million in 2024.